TY - JOUR
T1 - Evidence from routine clinical practice
T2 - EMPRISE provides a new perspective on CVOTs
AU - Schernthaner, Guntram
AU - Karasik, Avraham
AU - Abraitienė, Agne
AU - Ametov, Alexander S.
AU - Gaàl, Zsolt
AU - Gumprecht, Janusz
AU - Janež, Andrej
AU - Kaser, Susanne
AU - Lalić, Katarina
AU - Mankovsky, Boris N.
AU - Moshkovich, Evgeny
AU - Past, Marju
AU - Prázný, Martin
AU - Radulian, Gabriela
AU - Smirčić Duvnjak, Lea
AU - Tkáč, Ivan
AU - Trušinskis, Kārlis
N1 - Funding Information:
Editorial support was provided by Fortis Pharma Communications.
Funding Information:
Financial support was provided by Boehringer Ingelheim (BI). The opinions expressed are entirely the authors’own and the only involvement of BI was to have sight of the manuscript for accuracy.
Funding Information:
GS has previously received research grants and honoraria for speaking from Abbot, Amgen, Andromeda, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, DeveloGen, Eli Lilly, GlaxoSmithKline, Janssen, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Serono, Servier and Takeda. AK has received research support, lecture fees and served as advisory board member for Astra Zeneca, Boehringer Ingelheim and Novo Nordisk. ZG declares receipt of consultation fees from Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca and MSD; and Advisory board fees from Sanofi, Novo Nordisk, and Eli Lilly. JG has received speaker’s or consulting honoraria from Novo Nordisk, Eli Lilly, Servier, MSD, Bioton (Poland), Sanofi, Polpharma (Poland), Polfa Tarchomin (Poland), AstraZeneca and Boehringer Ingelheim. AJ has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk and Sanofi. SK declares research grants from MSD Austria and Boehringer Ingelheim RCV; consultancy fees or honoraria for speaking from AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, Novo Nordisk, Sanofi, Takeda and Mundipharma. BNM has been a member of Advisory Boards for Boehringer Ingelheim and Astra-Zeneca; and a member of a speaker bureau for Boehringer Ingelheim, Astra-Zeneca and Sanofi. EM is a lecturer for Boehringer Ingelheim, AstraZeneca, Sanofi, Novo Nordisk, MSD and Eli Lilly. MP2 has been a consultant or speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, Takeda and Teva. LSD declares receipt of consultation fees or participation in a company-sponsored speaker’s bureau for Novo Nordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Takeda, MSD and Merck. IT declares consultation and lecture fees from Boehringer Ingelheim, Eli Lilly, Mundipharma and Novo Nordisk. KT declares lecture honoraria and conference travel support from Boehringer Ingelheim. AA, ASA, GR, KL and MP1 declare no competing interests in relation to this article.
Publisher Copyright:
© 2019 The Author(s).
PY - 2019/8/31
Y1 - 2019/8/31
N2 - EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
AB - EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
KW - CVOTs
KW - EMPA-REG OUTCOME
KW - EMPRISE
KW - Heart failure
KW - Real-world evidence
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85071771613&partnerID=8YFLogxK
U2 - 10.1186/s12933-019-0920-3
DO - 10.1186/s12933-019-0920-3
M3 - Article
C2 - 31472683
AN - SCOPUS:85071771613
SN - 1475-2840
VL - 18
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
IS - 1
M1 - 115
ER -
